Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Editorial infographic highlighting Spruce Biosciences’ MPS IIIB disease progression research, featuring neurological imagery, enzyme therapy molecular models and laboratory equipment, with key milestones for TA-ERT development, a planned FDA filing and a confirmatory clinical trial.
Pharma & Biotech

Can Spruce Biosciences prove its Sanfilippo treatment slows brain decline? New data could strengthen its FDA case

Spruce Biosciences prepares MPS IIIB disease progression data as TA-ERT approaches its FDA filing and confirmatory trial milestones.

Read More
Editorial infographic highlighting LEO Pharma’s 21 dermatology research posters covering Anzupgo, Spevigo and Adbry, featuring skin tissue illustrations, clinical research imagery and key highlights on adolescent FDA review, clinical evidence and commercial growth prospects.
Pharma & Biotech

Why LEO Pharma is investing in real-world evidence for difficult dermatological diseases

LEO Pharma presents 21 dermatology posters covering Anzupgo, Spevigo and Adbry. Examine adolescent FDA review, clinical data and growth prospects.

Read More
Editorial infographic showing Bayer’s amyloidosis PET tracer results, with cardiac imaging, a PET scanner and laboratory visuals, highlighting 94% sensitivity in Phase III and new HFSA analyses on earlier diagnosis and finerenone treatment gaps.
Medical Devices & Diagnostics

Bayer’s experimental PET scan detected 94% of cardiac amyloidosis cases. Can it identify the disease earlier?

Bayer's amyloidosis PET tracer showed 94% sensitivity in Phase III. New HFSA analyses examine earlier diagnosis and finerenone treatment gaps.

Read More
Editorial infographic highlighting Ginkgo Bioworks’ involvement in the National Science Foundation’s $1.5 billion X-Labs initiative, featuring robotic laboratory automation, protein testing equipment and research infrastructure, with a clarification that the programme funding is not a contract award to Ginkgo.
Medical Devices & Diagnostics

Ginkgo Bioworks joins $1.5bn NSF X-Labs push with autonomous laboratory access

Ginkgo Bioworks will provide in-kind robotic laboratory access and protein testing services to researchers involved in the National Science Foundation's $1.5 billion X-Labs initiative. The announcement strengthens its position in publicly supported autonomous research infrastructure, but the programme's headline funding is not a contract award to Ginkgo.

Read More
Editorial infographic highlighting Guardant360 CDx’s European CE marking for ETCAMAH patient selection, featuring a blood sample tube, ESR1 mutation test results, breast cancer imagery and a European map illustrating the role of liquid biopsy in advanced breast cancer treatment.
Medical Devices & Diagnostics

How Guardant360 CDx detects ESR1 mutations before breast cancer progresses on imaging

Guardant360 CDx gains European CE marking for ETCAMAH patient selection. See how ESR1 blood testing changes advanced breast cancer treatment.

Read More
Editorial infographic illustrating BetterUp Canada's six-month virtual coaching study for first responders in Ontario, featuring a digital coaching platform, emergency response equipment, an Ontario map and graphics highlighting stress, resilience and workplace mental health.
Medical Devices & Diagnostics

BetterUp Canada launches Ontario Frontline Study to test mental health coaching

BetterUp Canada's Ontario study tests six months of virtual coaching for first responders, examining stress, resilience and workplace mental health.

Read More
Editorial infographic illustrating ME Therapeutics’ CD22 nanobody option extension to February 2027, featuring engineered immune cells, molecular biotechnology imagery and key highlights on dual-target CAR development, licensing opportunities and clinical development challenges.
Pharma & Biotech

Can ME Therapeutics’ CD19 CD22 CAR designs address resistance in B-cell cancers?

ME Therapeutics extends its CD22 nanobody option to February 2027. Examine dual-target CAR development, licensing and clinical challenges.

Read More
Pharma & Biotech

Can Accendra Health regain NYSE compliance before its April 2027 deadline?

Accendra Health faces a six-month NYSE deadline after ACH stock falls below $1. Examine reverse split options, debt and recovery risks.

Read More
Editorial infographic illustrating ALYFTREK’s reported pancreatic function gains in young children with cystic fibrosis, featuring a medical body diagram highlighting the pancreas, clinical charts and pediatric treatment imagery, with emphasis on potential implications for future care.
Pharma & Biotech

Vertex ALYFTREK data show pancreatic function recovery in young children with cystic fibrosis

Vertex reports pancreatic function gains with ALYFTREK in young children with cystic fibrosis. See what the results mean for future treatment.

Read More
Editorial infographic highlighting Seaport Therapeutics’ GlyphAgo, with laboratory imagery, capsule medication, a liver graphic and a bioavailability chart, showing 6.8-fold higher bioavailability, advancing anxiety trials and the still-unproven potential to reduce liver risks.
Pharma & Biotech

Can Seaport’s GlyphAgo overcome agomelatine’s liver problem? New Phase 1 data sharpen the test

Seaport's GlyphAgo shows 6.8-fold higher bioavailability as anxiety trials advance, but its potential to reduce liver risks remains unproven.

Read More